An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.

This study indicates that the recombinant protein dFv-ePD1 has an intensive melanoma-binding capability and exerts potent therapeutic efficacy against melanoma. The novel format of the PD-L1-blocked agent may play an active role in antitumor immunotherapy.
PMID: 30021673 [PubMed - as supplied by publisher]

Source: BMB Reports - July 19, 2018 Category: Biochemistry Authors: Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J, Wang Y, Qin Y Tags: BMB Rep Source Type: research